共被期刊论文引用了3次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2显示文摘Medical treatment has progressed significantly over the past decade towards achieving and maintaining clinical remission in patients with refractory ulcerative colitis(UC). Proposed mediators of inflammation in UC include pro-inflammatory cytokines such as tumor necrosis factor-α(TNF-α) and interleukin-2, and the cellsurface adhesive molecule integrin α4β7. Conventional therapeutics for active UC include 5-aminosalicylic acid, corticosteroids and purine analogues(azathioprine and 6-mercaptopurine). Patients who fail to respond to conventional therapy are treated with agents such as the calicineurin inhibitors cyclosporine and tacrolimus, the TNF-α inhibitors infliximab or adalimumab, or a neutralizing antibody(vedolizumab) directed against integrin α4β7. These therapeutic agents are of benefit for patients with refractory UC, but are not universally effective. Our recent research on TNF-α shedding demonstrated that inhibition of annexin(ANX) A2 may be a new therapeutic strategy for the prevention of TNF-α shedding during inflammatory bowel disease(IBD) inflammation. In this review, we provide an overview of therapeutic treatments that are effective and currently available for UC patients, as well as some that are likely to be available in the near future. We also propose the potential of ANX A2 as a new molecular target for IBD treatment. | Satoshi Tanida Tsutomu Mizoshita Keiji Ozeki Takahito Katano Hiromi Kataoka Takeshi Kamiya Takashi Joh | 2015 | World Journal of Gastroenterology2015，21，29： | 4 |
| 2 | 选择性白细胞分离法联合药物治疗对溃疡性结肠炎诱导缓解和维持治疗的荟萃分析显示文摘不同研究显示选择性白细胞分离法对溃疡性结肠炎(UC)的疗效差异很大.目的:系统性评价选择性白细胞分离法联合药物治疗对UC诱导缓解和维持治疗的作用.方法:检索PubMed、EMBASE、Cochrane Central Register of Controlled Trials、Science Citation Index和中文科技期刊数据库.纳入所有比较选择性白细胞分离法联合药物治疗与传统药物治疗对UC诱导缓解和维持治疗疗效的随机对照试验(RCTs).采用RevMan 5.0软件分析两者的诱导缓解率、维持缓解率和不良反应发生率.结果:共9项RCTs、685例患者符合人选标准,7项评估诱导缓解率,2项评估维持缓解率.选择性白细胞分离法联合药物治疗组的诱导缓解率显著高于传统药物治疗组(40.7%对29.1%,OR值为2.19,P〈0.0001),维持缓解率亦显著高于传统药物治疗组(70.4%对25.0%,OR值为8.14,P=0.002).选择性白细胞分离法联合药物治疗组的轻中度不良反应发生率明显低于传统药物治疗组(44.7%对65.3%,OR值为0.16,P=0.003).结论:与传统药物治疗相比,选择性白细胞分离法联合药物治疗能明显提高UC患者的诱导缓解率和维持缓解率,并能降低不良反应发生率. | 朱明明 徐锡涛 黄美兰 聂芳 冉志华 萧树东 | 2010 | 胃肠病学2010，15，10： | 3 |
| 3 | 血细胞分离术对溃疡性结肠炎诱导应答、缓解和维持缓解的meta分析显示文摘背景:血细胞分离术(CAP)逐渐用于溃疡性结肠炎(UC)的治疗,但其疗效尚无统一定论。目的:系统性评价CAP对UC患者的有效性和安全性。方法:计算机检索PubM ed、Embase、Web of Science、Cochrane Library、中国知网、万方和维普数据库,纳入所有关于CAP治疗UC的临床随机对照试验(RCTs)。由2名研究者独立选择文献、提取资料和文献质量评价后,采用RevM an 5.3软件进行meta分析。结果:共纳入20项研究1 354例UC患者。Meta分析结果显示,CAP诱导UC临床应答(RR=1.36,95%CI:1.20~1.55,P<0.000 01)、临床缓解(RR=1.38,95%CI:1.15~1.66,P=0.000 5)以及维持缓解(RR=2.92,95%CI:1.40~6.08,P=0.004)均明显优于传统治疗或假手术,而不良事件发生率无明显差异(RR=0.37,95%CI:0.11~1.24,P=0.110)。结论:CAP对诱导UC临床应答、缓解以及维持缓解具有较好的疗效,且安全性良好,但仍需大规模、多中心RCTs证实。 | 虞艳 顾雪香 向杰 黄光明 | 2017 | 胃肠病学2017，22，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员